These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 36739401)

  • 1. Epidemiology and comorbidities in idiopathic pulmonary fibrosis: a nationwide cohort study.
    Lee JH; Park HJ; Kim S; Kim YJ; Kim HC
    BMC Pulm Med; 2023 Feb; 23(1):54. PubMed ID: 36739401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and effectiveness of pirfenidone combined with carboplatin-based chemotherapy in patients with idiopathic pulmonary fibrosis and non-small cell lung cancer: A retrospective cohort study.
    Yamamoto Y; Yano Y; Kuge T; Okabe F; Ishijima M; Uenami T; Kanazu M; Akazawa Y; Yamaguchi T; Mori M
    Thorac Cancer; 2020 Nov; 11(11):3317-3325. PubMed ID: 32986306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone.
    Miura Y; Saito T; Tanaka T; Takoi H; Yatagai Y; Inomata M; Nei T; Saito Y; Gemma A; Azuma A
    Respir Investig; 2018 Jan; 56(1):72-79. PubMed ID: 29325685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H; Zhao Y; Li Z; Kang J
    Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study.
    Corral M; DeYoung K; Kong AM
    BMC Pulm Med; 2020 Jul; 20(1):188. PubMed ID: 32652979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study).
    Iwata T; Yoshino I; Yoshida S; Ikeda N; Tsuboi M; Asato Y; Katakami N; Sakamoto K; Yamashita Y; Okami J; Mitsudomi T; Yamashita M; Yokouchi H; Okubo K; Okada M; Takenoyama M; Chida M; Tomii K; Matsuura M; Azuma A; Iwasawa T; Kuwano K; Sakai S; Hiroshima K; Fukuoka J; Yoshimura K; Tada H; Nakagawa K; Nakanishi Y;
    Respir Res; 2016 Jul; 17(1):90. PubMed ID: 27450274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study.
    Majewski S; Białas AJ; Buchczyk M; Gomółka P; Górska K; Jagielska-Len H; Jarzemska A; Jassem E; Jastrzębski D; Kania A; Koprowski M; Krenke R; Kuś J; Lewandowska K; Martusewicz-Boros MM; Roszkowski-Śliż K; Siemińska A; Sładek K; Sobiecka M; Szewczyk K; Tomczak M; Tomkowski W; Wiatr E; Ziora D; Żołnowska B; Piotrowski WJ
    BMC Pulm Med; 2020 May; 20(1):122. PubMed ID: 32366291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of comorbid chronic kidney disease on mortality in idiopathic pulmonary fibrosis patients and influence of pirfenidone.
    Jo YS; Kim KJ; Rhee CK; Kim YH
    Sci Rep; 2023 Nov; 13(1):19238. PubMed ID: 37935732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study.
    Marijic P; Schwarzkopf L; Schwettmann L; Ruhnke T; Trudzinski F; Kreuter M
    Respir Res; 2021 Oct; 22(1):268. PubMed ID: 34666765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of pirfenidone in idiopathic pulmonary fibrosis according to the autoantibody status: a retrospective cohort study.
    Song MJ; Lee SH; Jung JY; Kang YA; Park MS; Kim YS; Chang J; Kim SY
    BMC Pulm Med; 2021 May; 21(1):145. PubMed ID: 33941141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venous thromboembolism in patients with idiopathic pulmonary fibrosis, based on nationwide claim data.
    Lee JH; Lee HH; Park HJ; Kim S; Kim YJ; Lee JS; Kim HC
    Ther Adv Respir Dis; 2023; 17():17534666231155772. PubMed ID: 36846942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idiopathic Pulmonary Fibrosis for Cardiologists: Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management.
    van Cleemput J; Sonaglioni A; Wuyts WA; Bengus M; Stauffer JL; Harari S
    Adv Ther; 2019 Feb; 36(2):298-317. PubMed ID: 30554332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative use of pirfenidone and reduced risk of postoperative severe respiratory complications in patients with idiopathic pulmonary fibrosis: Propensity score-matched analysis using a nationwide database in Japan.
    Urushiyama H; Jo T; Hasegawa W; Ando T; Sakamoto Y; Uda K; Matsui H; Fushimi K; Yasunaga H; Nagase T
    Respirology; 2021 Jun; 26(6):590-596. PubMed ID: 33870611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena.
    Vietri L; Cameli P; Perruzza M; Cekorja B; Bergantini L; d'Alessandro M; Refini RM; Pieroni M; Fossi A; Bennett D; Spalletti M; Mazzei MA; Sestini P; Rottoli P; Bargagli E
    Ther Adv Respir Dis; 2020; 14():1753466620906326. PubMed ID: 32066332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment.
    Noor S; Nawaz S; Chaudhuri N
    Adv Ther; 2021 Jan; 38(1):268-277. PubMed ID: 33098554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study.
    Tzouvelekis A; Ntolios P; Karampitsakos T; Tzilas V; Anevlavis S; Bouros E; Steiropoulos P; Koulouris N; Stratakos G; Froudarakis M; Bouros D
    Pulm Pharmacol Ther; 2017 Oct; 46():48-53. PubMed ID: 28843616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis.
    Ley B; Swigris J; Day BM; Stauffer JL; Raimundo K; Chou W; Collard HR
    Am J Respir Crit Care Med; 2017 Sep; 196(6):756-761. PubMed ID: 28471697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone.
    Ikeda K; Shiratori M; Chiba H; Nishikiori H; Yokoo K; Saito A; Hasegawa Y; Kuronuma K; Otsuka M; Yamada G; Takahashi H
    Respir Med; 2017 Oct; 131():184-191. PubMed ID: 28947028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone.
    Kreuter M; Spagnolo P; Wuyts W; Renzoni E; Koschel D; Bonella F; Maher TM; Kolb M; Weycker D; Kirchgässler KU; Costabel U
    Respiration; 2017; 93(6):415-423. PubMed ID: 28399537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre.
    Bargagli E; Piccioli C; Rosi E; Torricelli E; Turi L; Piccioli E; Pistolesi M; Ferrari K; Voltolini L
    Pulmonology; 2019; 25(3):149-153. PubMed ID: 30236523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.